Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on September 2, 2020. The report addresses a compliance issue with The Nasdaq Stock Market LLC regarding minimum stockholders' equity requirements and details corporate transactions executed on September 1, 2020, to resolve this deficiency.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures. The primary financial metric disclosed is stockholders' equity.
- Stockholders' Equity: The Company believes its stockholders' equity exceeded $5 million as of September 2, 2020, following recent transactions.
- Previous Deficiency: The Company previously failed to maintain the required minimum of $2,500,000 in stockholders' equity under Nasdaq Listing Rule 5550(b)(1).
Material Changes
On September 1, 2020, the Company consummated two significant transactions (collectively, the "Transactions") to increase equity:
- Preferred Stock Exchange: Exchanged 5,524,926 shares of Series A Convertible Participating Preferred Stock for 842,500 shares of Series C Perpetual Preferred Stock and 842,500 shares of Series D Perpetual Preferred Stock with Iliad Research and Trading, L.P.
- Common Stock Issuance: Issued 2,289,474 shares of common stock to Sagard Capital Partners, L.P. pursuant to a Stock Plan Agreement for Payment of Consulting Services.
These actions were taken to meet the $5 million minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market.
Outlook, Risks, and Forward-Looking Statements
The Company issued a press release on September 2, 2020, announcing the increase in stockholders' equity. The filing contains forward-looking statements regarding the belief that equity now exceeds $5 million. The Company cautions that actual results may differ materially from expectations due to various risk factors detailed in its Annual Report on Form 10-K for the year ended December 31, 2019. The Company assumes no obligation to update these statements.
Investor Verification Checklist
- Verify the final audited stockholders' equity balance to confirm it sustains the $5 million threshold.
- Review the Exchange Agreement with Iliad Research and Trading, L.P. for terms regarding the Series C and Series D Preferred Stock.
- Examine the Stock Plan Agreement with Sagard Capital Partners to understand the valuation and terms of the consulting services.
- Monitor subsequent correspondence from Nasdaq regarding the reinstatement of listing compliance.